Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 4245  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  ╗  Similar in PUBMED
 ╗  Search Pubmed for
 ╗  Search in Google Scholar for
 ╗Related articles
  ╗  Article in PDF (538 KB)
  ╗  Citation Manager
  ╗  Access Statistics
  ╗  Reader Comments
  ╗  Email Alert *
  ╗  Add to My List *
* Registration required (free)  

 
  In this Article
   Abstract
   Introduction
   Material and Methods
   Results
   Discussion
   Acknowledgment
   References
   Article Tables

 Article Access Statistics
    Viewed2509    
    Printed187    
    Emailed2    
    PDF Downloaded88    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 


 
Table of Contents    
TOPIC OF THE ISSUE: ORIGINAL ARTICLE
Year : 2011  |  Volume : 59  |  Issue : 2  |  Page : 236-240

Matrix metalloproteinase-2 gene polymorphism is not associated with increased glioblastoma multiforme susceptibility: An Indian institutional experience


Department of Neurosurgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Date of Submission17-Aug-2010
Date of Decision22-Sep-2010
Date of Acceptance06-Oct-2010
Date of Web Publication7-Apr-2011

Correspondence Address:
Raj Kumar
Department of Neurosurgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.79131

Rights and Permissions

 ╗ Abstract 

Background: Glioblastoma multiforme (GBM) is a highly malignant central nervous system tumor that is extremely refractory to therapy due to its rapid growth and local invasive potential. The ability of glioma cells to invade the surrounding tissue has been attributed to the expression of matrix metalloproteinase-2 (MMP-2) in human gliomas. The -1306C/T polymorphism in the MMP-2 gene has been found to be associated with gastric adenocarcinoma, lung cancer and various other cancers including GBM. Racial and ethnic variations are known in such genetic polymorphisms. Aims: This prospective, case control study was aimed to find out an association of MMP-2 gene polymorphism with susceptibility to develop glioblastoma in Indian population. Material and Methods: MMP-2 gene polymorphism was studied using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 110 GBM patients and 150 healthy controls. The SPSS 17.0 statistical software (Chicago, IL, USA) was used for data management and analysis Results and Conclusions: A significant association of MMP-2 (−1306C/T) polymorphism with GBM (P = 0.475) was not found, suggesting that MMP-2 (−1306C/T) polymorphism is not associated with increased GBM susceptibility.


Keywords: Gene polymorphism, glioblastoma multiforme, MMP-2


How to cite this article:
Kumar R, Malik N, Tungaria A, Kawal P. Matrix metalloproteinase-2 gene polymorphism is not associated with increased glioblastoma multiforme susceptibility: An Indian institutional experience. Neurol India 2011;59:236-40

How to cite this URL:
Kumar R, Malik N, Tungaria A, Kawal P. Matrix metalloproteinase-2 gene polymorphism is not associated with increased glioblastoma multiforme susceptibility: An Indian institutional experience. Neurol India [serial online] 2011 [cited 2019 Aug 25];59:236-40. Available from: http://www.neurologyindia.com/text.asp?2011/59/2/236/79131



 ╗ Introduction Top


Glioblastoma, the most common intrinsic malignant brain tumor. [1] is characterized by excessive proliferation, high invasion of the surrounding brain tissue, and suppression of anti-tumor immune surveillance. which contribute to the malignant phenotype of gliomas. Even low-grade gliomas infiltrate the contiguous brain; a key feature which precludes their successful therapy. Interaction of integrins expressed on glioma cells with the extracellular matrix and the activity of metalloproteinases (MMPs) are prerequisites for the migration and invasion of glioma cells. [2],[3] MMPs are a growing family of zinc-dependent endopeptidases belonging to subfamily M10A, which are capable of degrading various components of the extracellular matrix including collagens, laminin, fibronectin, vitronectin and proteoglycans. These enzymes have been implicated in a variety of physiological and pathological conditions including embryogenesis, tumor invasion and metastasis. The regulation of MMP expression is complex. The synthesis of many MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), is thought to be regulated by growth factors, cytokines and hormones. MMP-2 and MMP-9 have been well studied in gliomas, particularly because these enzymes are easy to measure by gelatin zymography. A large body of literature reports that MMP-2 and MMP-9 are upregulated in glioma specimens in vitro and in vivo.[4],[5],[6],[7],[8] MMP-2, a 72 kDa gelatinase, degrades non-fibrillar and denatured collagens (primarily type IV collagen), and is secreted as a latent pro-form which is processed into the active molecule through interaction with membrane-type1-MMP (MT1-MMP) on the cell surface, and the interaction is regulated by TIMP. [9]

MMP-2 also has high activity toward many other bioactive molecules such as growth factor-binding proteins and growth factor receptors, which are well known to have a strong effect on stimulating cell proliferation and inhibiting apoptosis. These activities of MMP-2 are believed to be linked to both cancer development and progression. [10] The cancers in which an effect for MMP-2 has been established are characterized by varying individual susceptibility, implying the role of genetic factors. However, like many MMPs, MMP-2 is not upregulated by gene amplification or activating mutations, and genetic alternations in the gene of the cancer cells are generally lacking. Therefore, germ-line polymorphisms that alter constitutive and/or induced expression and enzyme activity of MMP-2 may affect individual susceptibility to certain cancers. [11]

Price et al., described the nature and extent of nucleotide variation in the human MMP-2 gene by identifying 15 novel single nucleotide polymorphisms (SNPs) distributed throughout the coding and non-coding regions. The common C → T transition at −1306, which disrupts an Sp1-type promoter site (CCACC box), displayed a strikingly lower promoter activity with the T allele. [12] This suggests that this common functional genetic variant influences MMP-2 gene transcription in an allele-specific manner and is therefore an important candidate to test for association in a wide spectrum of pathologies for which a role for MMP-2 is implicated, including atherogenesis and tumor invasion and metastasis. In fact, it has been shown in various studies that frequency of −1306 MMP-2 (C/T) polymorphism is significantly higher in patients of lung cancer, gastroesophageal cancer, breast cancer, invasive bladder cancer and cervix cancer. [13],[14],[15],[16],[17],[18],[19]

The data on strength of association between −1306 MMP-2 polymorphism and glioblastoma multiforme (GBM) in Indian population are not available. Therefore, the present study was carried out to look for the association of MMP-2 gene polymorphism with susceptibility of developing glioblastoma in Indian population. The study, in addition, also provides −1306 MMP-2 genotype pools in normal Indian population as a baseline for further studies on the subject pertaining to various diseases.


 ╗ Material and Methods Top


Study population

This study subjects included 110 patients with GBM (mean age ± SD, 37.01 ± 14.62 years; male:female, 81:29) and 150 age-gender matched healthy controls (mean age ± SD, 39.87 ± 11.85). All subjects were ethnic Indians. GBM patients were selected on the basis of histopathological confirmation of the tumor tissue by the department of pathology. In the patient population, we did not include any patient who was reoperated or with an evidence of malignant transformation from a lower grade to GBM or with a presenting history of longer duration (>4 months). The Institutional Ethics Committee (IEC, SGPGIMS) granted approval for the study and informed consent was obtained from all the study subjects.

DNA extraction

Genomic DNA was extracted from ethylenediaminetetraacetic acid (EDTA) anticoagulated peripheral blood by salting-out method [20] and stored at −20°C till further use. DNA samples of 10 ng/μl concentration were used for the detection of SNPs.

MMP-2 (−1306 C/T) genotyping

MMP-2 genotypes were determined by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) based method, as previously described. [21] The primer sequences for MMP-2 were: forward 5'-ATAGGGTAAACCTCCCCACATT-3' and reverse 5′-GGTAAAATGAGGCTGAGACCTG -3′ (Bangalore Genei, India). All PCR amplifications were performed in a 20 μl volume containing 10× assay buffer, 200 μM each dATP, dCTP, dGTP, dTTP, 0.1 μM each primer, and 1.0 U Taq DNA polymerase (Bangalore Genei, India). PCR conditions were as follows: an initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 65°C for 30 seconds, and extension at 72°C for 30 seconds, followed by final extension step at 72°C for 5 min and cooling to 4°C. Template free water was used as a negative control. After amplification, the purified 4 μl PCR products were subjected to restriction digestion by Eco RI restriction endonuclease (Fermentas, Vilnius, Lithuania) for MMP-2 polymorphism with 1 μl 10× enzyme buffer (Fermentas) overnight at 37°C. The digested DNA fragments were then separated on 3% agarose gel electrophoresis. After digestion, fragment sizes for carriers of the polymorphic allele decreased from 300 bp (wild-type) to 300 bp, 254 bp, and 46 bp (heterozygous) and to 254 bp, 46 bp (variant). All the experiments were repeated twice for confirmation of the RFLP results. No discrepancy was found after sequencing of the 10% randomly selected samples.

Statistical analysis

The SPSS 17.0 statistical software (Chicago, IL, USA) was used for data management and analysis. Hardy-Weinberg equilibrium was checked in controls by goodness of fit c2 test. For comparisons between the groups of study populations, χ2 test was used. Logistic regression analysis was applied to estimate association with GBM susceptibility after adjusting for age and gender. P value ≤0.05 was considered significant.


 ╗ Results Top


Characteristics of GBM patients and control subjects

In present study, age was comparable in GBM patients and control groups (39.87 ± 11.85 vs. 37.01 ± 14.62 years, P > 0.05). No significant difference was present with respect to gender (male/female = 81/29 in patients and 99/51 in controls (P > 0.05 for both) [Table 1]. The MMP-2 polymorphism was in agreement with Hardy-Weinberg equilibrium in control subjects.
Table 1: Demographics of study subjects

Click here to view


MMP-2 (−1306C/T) polymorphisms and GBM

The genotype frequency was compared between patients and controls to analyze the association of MMP-2 (−1306C/T) polymorphism with GBM susceptibility. The genotypic distribution of MMP-2 (−1306C/T) polymorphism demonstrated no association of GBM susceptibility in patients with C/T (OR, 0.807; P = 0.475; 95% CI, 0.44-1.45) as well as with T/T (OR, 1.19; P = 0.865; 95% CI, 0.16-8.94) genotypes compared to normal subjects. Patients with GBM showed almost similar prevalence of T allele of −1306 MMP-2 gene polymorphism (12.7 vs. 14.3%, OR, 8.73; P = 0.598; 95% CI, 0.52-1.45) compared to controls [Table 2].
Table 2: Influence of MMP-2 polymorphisms on glioblstoma multiforme susceptibility

Click here to view



 ╗ Discussion Top


The present study was aimed to find out the association of MMP-2 (−1306C/T) gene polymorphism with GBM susceptibility. We showed for the first time that −1306 MMP-2 gene polymorphism is not significantly associated with GBM patients compared to controls from northern Indian population. However, an association of −1306 MMP-2 gene polymorphism with various other malignancies has been demonstrated. [13],[14],[15],[16],[17],[18],[19]

MMP-2 (gelatinase A) has type IV collagenolytic activity and is constitutively expressed by most connective tissue cells including endothelial cells, osteoblasts, fibroblasts and myoblasts. The membrane-bound activation of pro-MMP-2 through its proteolytic activity against components of the basement membrane executes extracellular matrix remodeling as well as uniquely generates several different biologically active molecules including laminin, fibronectin, and monocyte chemoattractant protein-3. [22],[23],[24],[25] Majority of studies concerning MMP-2 have focused on demonstrating its essential role in promoting cell invasiveness during tumor angiogenesis as well as tumor metastasis. [26],[27],[28],[29],[30]

GBM is a highly malignant central nervous system tumor that is extremely refractory to therapy due its rapid growth and local invasive potential. This rapid infiltrative growth prevents successful surgical resection of GBM. The ability of glioma cells to invade the surrounding tissue has been attributed to their secretion of MMPs. In vivo studies have demonstrated the expression of MMP-2 in human gliomas. [31],[32],[33],[34],[35] MMP-2 expression was the highest in high grade gliomas (GBM, anaplastic astrocytoma) as compared to low grade astrocytomas and normal brain. [31],[35],[36]

Cancers in which a role for MMP-2 has been demonstrated are generally characterized by various individual susceptibilities, implying the role of genetic factors. A functional SNP in MMP-2 has been reported: [12] a −1306C → T transition in the MMP-2 promoter sequence disrupts an Sp1-type promoter site (CCACC box), and thus displays a strikingly lower promoter activity with the T allele in an in vitro assay system. [12] It has been suggested that the −1306C/T polymorphism in the MMP-2 gene may be informative in a test of association with cancer development in which a role for MMP-2 is implicated. This functional polymorphism has been demonstrated in various cancers. [13],[14],[15],[16],[17],[18],[19] If this polymorphism actually causes variations in transcription and expression of MMP-2 in vivo, it might affect individual susceptibility to carcinogenesis.

The variant allele (T) of this polymorphism was not significantly associated with susceptibility of developing GBM in our study population. Such genetic polymorphisms are known to be affected by racial and ethnic variations. To add, this study also shows that CC is the most frequent genotype of −1306 MMP-2 gene polymorphism in both GBM as well as in normal subjects (76.4 and 72.7%, respectively). These data on genotype pool shall be useful for further studies on Indian population.

Although the −1306 MMP-2 gene polymorphism has been shown to be associated with other cancers such as esophageal, lung, breast, prostrate, invasive bladder cancer and gastric cardia adenocarcinoma as well as brain cancer, [6],[13],[14],[15],[16],[17],[18],[19] however, this pilot study has not shown any association of −1306 MMP-2 gene polymorphism with GBM in Indian population (P = 0.475). This disagreement in the present study is most likely due to small sample size and also can be attributed to racial and ethnic variations in different populations. It would therefore be rational to confirm these findings by a large population-based prospective study to settle the controversy. The results, however, may also be a pointer toward the greater significance of haplotypes of MMP-2 gene with genes on adjacent loci rather than SNP of MMP-2 gene only. In addition, other factors such as exposure to toxic chemicals, radiation, and electromagnetic fields have been implicated by some in the pathogenesis of these tumors. These factors might interact with MMP-2 genotype or act as potential confounders in the analysis. Unfortunately, information on these factors in this study was not available.

To summarize, this study remains a pilot study to find the association of MMP-2 gene polymorphism with GBM and more efforts in different geographic ethnic groups are required in larger population to reach a firm conclusion.


 ╗ Acknowledgment Top


The authors are cordially thankful to Kishan K. Nyati for his kind cooperation and support during experimental laboratory work.

 
 ╗ References Top

1.Russell DS, Rubenstein LJ. Pathology of Tumours of the Nervous System. 5th ed. Baltimore: Williams and Wilkins; 1989. p. 83-289.  Back to cited text no. 1
    
2.Deryogina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997;110:2473-82.  Back to cited text no. 2
    
3.Goldbrunner RH, Bernstein JJ, Tonn JC. ECM-mediated glioma cell invasion. Microsc Res Tech 1998;43:250-7.   Back to cited text no. 3
    
4.Rao J. Molecular mechanism of glioma invasiveness: The role of proteases. Nat Rev Cancer 2003;3:489-501.  Back to cited text no. 4
    
5.Uhm JH, Dooley NP, Villemure JG, Yong VW. Glioma invasion in vitro: Regulation by matrix matelloproteas-2 and protein kinase. Clin Exp Metastasis 1996;14:421-33.  Back to cited text no. 5
    
6.Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, et al. Gelatinase-A (MMP-2), Gelatinase -B (MMP-9) and membrane type matrix metalloproteinase-1 are involved in different aspects of the pathophysiology of malignant glioma. Br J Cancer 1999;79:1828-35.  Back to cited text no. 6
    
7.Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinase and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001;60:598-612.  Back to cited text no. 7
    
8.Yong VW, Power C, Forsyth P, Edward DR. Metalloproteinases in biology and pathology of nervous system. Nat Rev Neurosci 2001;2:502-11.   Back to cited text no. 8
    
9.Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998;58:3743-50.  Back to cited text no. 9
    
10.Egeblad M, Werb Z. New functions for the matrix matelloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.  Back to cited text no. 10
    
11.Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (- 1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 2003;63:3987-90.  Back to cited text no. 11
    
12.Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: Role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-58.  Back to cited text no. 12
    
13.Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, et al. Correlation between a single nucleotide polymorphism in the Matrix Metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002;62:6430-3.  Back to cited text no. 13
    
14.Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.  Back to cited text no. 14
    
15.Parsons SL, Watson SA, Collins HM, Griffin NR, Clarke PA, Steele RJ. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 1998;78:1495-502.  Back to cited text no. 15
    
16.Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y. Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 2000;36:2164-70.  Back to cited text no. 16
    
17.Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, Bautista-Lam JR, Andrade-Soto M, Jonguitud-Olguin G, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 2008;65:68-72.  Back to cited text no. 17
    
18.Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 2007;13:2614-20.  Back to cited text no. 18
    
19.Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, et al. Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet 2008;46:137-44.  Back to cited text no. 19
    
20.Miller SA, Dykes DD, Polesky HF. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.  Back to cited text no. 20
    
21.Gonzalez-Hernandez NA, Millan-Guerrero RO, Ceja-Espiritu G, Baltazar-Rodriguez LM, Rodriguez-Salazar R, Olmedo-Buenrostro BA, et al. A polymorphism in the matrix metalloproteinase-2 (MMP-2 -1306T>C) gene promoter is associated with high risk of ischemic stroke in hypertensive patients. Genes Genom 2008;30:33-540.  Back to cited text no. 21
    
22.Giannelli G, Falk MJ, Schiraldi O, Stetler Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.  Back to cited text no. 22
    
23.Zuo J, Ferguson TA, Hernandez YJ, Stetler Stevenson WG, Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J Neurosci 1998;18:5203-11.  Back to cited text no. 23
    
24.Watanabe K, Takahashi H, Habu Y, Kamiya KN, Kamiya S, Nakamura H, et al. Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry 2000;39:7138-44.  Back to cited text no. 24
    
25.McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6.  Back to cited text no. 25
    
26.Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-9.  Back to cited text no. 26
    
27.Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.  Back to cited text no. 27
    
28.Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.  Back to cited text no. 28
    
29.Barger AC, Beeuwkes RD, Lainey LL, Silverman KJ. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984;310:175-7.  Back to cited text no. 29
    
30.Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.  Back to cited text no. 30
    
31.Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995;83:298-307.  Back to cited text no. 31
    
32.Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Seiki M, Sato H, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-92.  Back to cited text no. 32
    
33.Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.  Back to cited text no. 33
    
34.Mohanam S, Wang SW, Rayford A, Yamamoto M, Sawaya R, Nakajima M, et al. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 1995;13:57-62.  Back to cited text no. 34
    
35.Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 1996;14:35-42.  Back to cited text no. 35
    
36.Rao JS, Yamamoto M, Mohaman S, Gokaslan ZL, Fuller GN, Stetler-Stevenson WG, et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996;14:12-8.  Back to cited text no. 36
    



 
 
    Tables

  [Table 1], [Table 2]

This article has been cited by
1 Role of MMP-2 (-1306?C/T) Polymorphism in Pituitary Adenoma
Brigita Glebauskiene,Rasa Liutkeviciene,Alvita Vilkeviciute,Loresa Kriauciuniene,Giedrimantas Bernotas,Arimantas Tamasauskas,Dalia Zaliuniene
Scientifica. 2016; 2016: 1
[Pubmed] | [DOI]
2 Matrix Metalloproteinase-2 -1306 C>T Gene Polymorphism is Associated with Reduced Risk of Cancer: a Meta-analysis
Shafiul Haque,Naseem Akhter,Mohtashim Lohani,Arif Ali,Raju K. Mandal
Asian Pacific Journal of Cancer Prevention. 2015; 16(3): 889
[Pubmed] | [DOI]
3 Presence ofmatrix metalloproteinaseľ2andtissue inhibitor matrix metalloproteinaseľ2gene polymorphisms and immunohistochemical expressions in intracranial meningiomas
Ilker Coven,Ozge Ozer,Ozlem Ozen,Feride Iffet Sahin,Nur Altinors
Journal of Neurosurgery. 2014; : 1
[Pubmed] | [DOI]
4 Matrix metalloproteinases
Chacko, G.
Neurology India. 2011; 59(2): 224-225
[Pubmed]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow